Enfortumab Vedotin in urothelial cancer

Alt, Marie; Stecca, Carlos; Tobin, Swanee; Jiang, Di Maria; Sridhar, Srinivas

doi:10.1177/1756287220980192

Cited by 26 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enfortumab vedotin is composed of a fully human monoclonal antibody against nectin-4, a type I transmembrane cell adhesion protein that is highly expressed in a number of epithelial cancers, including urothelial cancer, and monomethyl auristatin E, an anti-cancer agent that disrupts microtubule formation in cancer cells ( 8 ). The ADC is a new type of anti-cancer agent, and the linker plays the important role of attaching the monoclonal antibody to the cytotoxic agent ( 32 , 33 ). The linker is stable in the bloodstream and releases the drug into the cells only after binding to the target.…”

Section: Urothelial Cancermentioning

confidence: 99%

Recent Advances in Medical Therapy for Urological Cancers

2022

View full text Add to dashboard Cite

The mainstay of medical treatment has been tyrosine kinase inhibitors (TKIs) for renal cell cancer (RCC), cytotoxic chemotherapy for urothelial cancer (UC), and androgen deprivation therapy for prostate cancer. These therapeutic modalities still play important roles in these malignancies. However, immune checkpoint inhibitors (ICIs) that target PD-1/PD-L1 or CTLA-4 are being rapidly introduced for the treatment of metastatic urological cancers, just as they have been for other malignancies. Currently, the paradigm of medical treatment for patients with metastatic urological cancer is dramatically changing. Accordingly, we need to organize and summarize the new therapeutic tools, which include immune checkpoint inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and antibody-drug conjugates (ADCs). This review provides an overview of agents and regimens that have just launched or will be launched in the near future in Japan. Based on the promising anti-tumor efficacy and manageable safety profiles being demonstrated in clinical trials, these new agents and therapies are expected to be rapidly introduced in Japanese clinical practice. Additionally, the newly designed ADC, enfortumab vedotin, which comprises a fully human monoclonal antibody conjugated to an anti-cancerous agent via a protease-cleavable linker, has just been launched in Japan. In order to provide the optimal treatment for our patients, we need to completely understand these new therapeutic tools.

show abstract

Section: Urothelial Cancermentioning

confidence: 99%

Recent Advances in Medical Therapy for Urological Cancers

2022

View full text Add to dashboard Cite

show abstract

“…This is a humanized anti-trophoblast cell-surface antigen 2 (Trop 2) antibody, conjugated with SN-38, an active metabolite of irinotecan that inhibits the nuclear topoisomerase 1, inducing double-stranded DNA breaks and, ultimately, cell death. 54 , 55 …”

Section: Subsequent Lines Of Therapymentioning

confidence: 99%

Metastatic Urothelial Cancer: a rapidly changing treatment landscape

2021

Self Cite

View full text Add to dashboard Cite

Despite significant progress, metastatic urothelial cancer remains an incurable condition with a limited life expectancy. Platinum-based chemotherapy is still the mainstay of treatment for metastatic disease, but immunotherapy, antibody drug conjugates, and targeted agents have shown encouraging results in several recent practice changing trials. In this review, we discuss the standard of care, recent therapeutic advances, ongoing clinical trials, and future perspectives in metastatic urothelial carcinoma.

show abstract

“…Because nectin-4 is highly expressed in all metastatic UC tumors, once the bonded enfortumab vedotin is internalized, the microtubule-disrupting agent MMAE is released leading to apoptosis of the tumor cell. Clinical trials demonstrated enfortumab vedotin is a new therapeutic method in patients with platinum-and immune checkpoint inhibitor-refractory disease (70,71).…”

Section: Bladder Cancer Genomics and Precision Treatmentmentioning

confidence: 99%

Frontiers in Bladder Cancer Genomic Research

Sun

Guo

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Most of the etiology studies of bladder cancer focus on genetic changes, mainly including mutation and activation of oncogenes, mutation and inactivation of tumor suppressor genes, and rearrangement or heterozygous deletion of chromosomes. Moreover, bladder cancer is highly heterogeneous mainly due to abnormal changes in the genome and proteome of tumor cells. Surgery is the main treatment for bladder cancer, but because the recurrence rate is high after surgery and most of the muscle-invasive bladder cancer acquires distant metastasis. Therefore, there is a need to combine with chemotherapy to consolidate the treatment effect. However, there are differences in chemosensitivity among patients. In this article, we review the up-to-date genomic researches on bladder cancer occurrence, development, metastasis, and chemosensitivity in patients, in order to provide some theoretical support for the diagnosis and treatment strategy for bladder cancer.

show abstract

Enfortumab Vedotin in urothelial cancer

Cited by 26 publications

References 25 publications

Recent Advances in Medical Therapy for Urological Cancers

Recent Advances in Medical Therapy for Urological Cancers

Metastatic Urothelial Cancer: a rapidly changing treatment landscape

Frontiers in Bladder Cancer Genomic Research

Contact Info

Product

Resources

About